Filana Therapeutics, Inc. (FLNA) Stock Score, Valuation & Financial Research

Filana Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for FLNA

Filana Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.77. These figures are a research snapshot, not a buy or sell recommendation.

What Filana Therapeutics, Inc. does

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Filana Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of proprietary small molecule drug candidates, specifically targeting the filamin A protein for the treatment of central nervous system disorders, and it relies on capital raises to fund these operations.

Products and services

  • The company's primary product candidate is simufilam, a proprietary small molecule oral treatment currently being studied for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy.

Brands and product families

  • Simufilam — Lead therapeutic drug candidate being studied for the treatment of TSC-related epilepsy. Source

Customer types

Patients with central nervous system disorders.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes various third-party contract research organizations to conduct clinical trials and research activities; the specific names of these suppliers are not disclosed. Source

Business strengths to evaluate

  • Proprietary intellectual property portfolio including issued patents and pending applications for simufilam Source

Business risks and research considerations

  • Inherent risks in drug discovery and development Source
  • Dependence on the ability to obtain, maintain, and enforce intellectual property protection Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

FLNA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.77
Market capitalization:
37.17M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -42.28M
Free cash flow:
USD -32.83M
Cash:
USD 82.68M
Total debt:
USD 0.00
EPS:
USD -0.87

What stands out

  • Free cash flow is USD -32.83M, negative for the stored period.
  • The balance sheet shows USD 82.68M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 82.68M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for FLNA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can FLNA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is FLNA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for FLNA to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of FLNA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 45% of the scoring inputs required for this public page are currently available.

How to research FLNA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.